| Study cohort | No CMV events | CMV events | |
| N = 139 | N = 76 | N = 63 | |
| Age (years) | |||
| Mean ± SD | 49.8 ± 12.64 | ||
| Sex (male) | 83 (60%) | 47 (62%) | 36 (57%) |
| Underlying disease | |||
| Idiopathic pulmonary fibrosis | 59 (42.4%) | 33 (43%) | 26 (40%) |
| Chronic obstructive pulmonary disease | 35 (25.2%) | 17 (22%) | 18 (28%) |
| Cystic fibrosis | 14 (10%) | 11 (14%) | 3 (5%) |
| Miscellaneous | 31 (22.4%) | 15 (21%) | 16 (25%) |
| Types of transplant | |||
| Single lung | 96 (69%) | 49 (64%) | 46 (73%) |
| Double lung | 43 (31%) | 26 (36%) | 17 (27%) |
| Duration of prophylaxis (months) Median (min. - max.) | 4 (1.5 - 9) | ||
| Donor/receptor serological status | |||
| CMV D+/R- | 15 (10.7%) | 6 (8%) | 9 (14%) |
| CMV D-/R- | 16 (11.5%) | 13 (17%) | 3 (5%) |
| CMV D-/R+ | 25 (18%) | 17 (22%) | 8 (13%) |
| CMV D+/R+ | 83 (57%) | 40 (53%) | 43 (68%) |
| Rejection requiring increased immunosuppression | 47 (34%) | 26 (34%) | 21(33%) |